Browsing Breast Cancer Research by author "Campbell, James"
Now showing items 21-25 of 25
-
Modeling Therapy Resistance in BRCA1/2-Mutant Cancers.
Dréan, A; Williamson, CT; Brough, R; Brandsma, I; Menon, M; et al. (AMER ASSOC CANCER RESEARCH, 2017-09-01)Although PARP inhibitors target BRCA1- or BRCA2-mutant tumor cells, drug resistance is a problem. PARP inhibitor resistance is sometimes associated with the presence of secondary or "revertant" mutations in BRCA1 or BRCA2 ... -
Optimised ARID1A immunohistochemistry is an accurate predictor of ARID1A mutational status in gynaecological cancers.
Khalique, S; Naidoo, K; Attygalle, AD; Kriplani, D; Daley, F; et al. (WILEY, 2018-07-20)ARID1A is a tumour suppressor gene that is frequently mutated in clear cell and endometrioid carcinomas of the ovary and endometrium and is an important clinical biomarker for novel treatment approaches for patients with ... -
Synthetic Lethal Targeting of ARID1A-Mutant Ovarian Clear Cell Tumors with Dasatinib.
Miller, RE; Brough, R; Bajrami, I; Williamson, CT; McDade, S; et al. (AMER ASSOC CANCER RESEARCH, 2016-07-01)New targeted approaches to ovarian clear cell carcinomas (OCCC) are needed, given the limited treatment options in this disease and the poor response to standard chemotherapy. Using a series of high-throughput cell-based ... -
Therapeutic vulnerabilities in the DNA damage response for the treatment of ATRX mutant neuroblastoma.
George, SL; Lorenzi, F; King, D; Hartlieb, S; Campbell, J; et al. (ELSEVIER, 2020-09-01)BACKGROUND: In neuroblastoma, genetic alterations in ATRX, define a distinct poor outcome patient subgroup. Despite the need for new therapies, there is a lack of available models and a dearth of pre-clinical research. ... -
Three-dimensional modelling identifies novel genetic dependencies associated with breast cancer progression in the isogenic MCF10 model.
Maguire, SL; Peck, B; Wai, PT; Campbell, J; Barker, H; et al. (WILEY, 2016-11-01)The initiation and progression of breast cancer from the transformation of the normal epithelium to ductal carcinoma in situ (DCIS) and invasive disease is a complex process involving the acquisition of genetic alterations ...